Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

iTeos Therapeutics, Inc. (ITOS)

19.93   -0.23 (-1.14%) 11-25 13:00
Open: 20.17 Pre. Close: 20.16
High: 20.17 Low: 19.4
Volume: 69,471 Market Cap: 709(M)

Technical analysis

as of: 2022-11-25 1:58:07 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 24.07     One year: 25.92
Support: Support1: 18.04    Support2: 15
Resistance: Resistance1: 20.61    Resistance2: 22.2
Pivot: 20.24
Moving Average: MA(5): 20.44     MA(20): 20.02
MA(100): 21.66     MA(250): 27.31
MACD: MACD(12,26): 0.3     Signal(9): 0.3
Stochastic oscillator: %K(14,3): 44.1     %D(3): 53.7
RSI: RSI(14): 49.5
52-week: High: 52.43  Low: 16.2
Average Vol(K): 3-Month: 307 (K)  10-Days: 280 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ITOS ] has closed above bottom band by 42.4%. Bollinger Bands are 2.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 20.49 - 20.63 20.63 - 20.74
Low: 19.44 - 19.59 19.59 - 19.71
Close: 19.96 - 20.2 20.2 - 20.38

Company Description

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Headline News

Wed, 23 Nov 2022
JESSE’S VISUAL INTERVIEWS: Dai Ito - Japan Camera Hunter

Wed, 23 Nov 2022
Germany v Japan ratings: Gundogan 6, Muller 7; Asano 8, Ito 8 - The National

Mon, 21 Nov 2022
A Liz Truss Moment for Japan? by Takatoshi Ito - Project Syndicate

Sat, 19 Nov 2022
FEATURE | World Cup One to Watch: Junya Ito – Get French Football News - Get French Football News

Fri, 18 Nov 2022
Roma prepare bid for Stuttgart defender Hiroki Ito -

Fri, 18 Nov 2022
New 'Junji Ito Maniac' Teaser Showcases the Subtle Scares of Netflix's Upcoming Horror Anime - Collider

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 36 (M)
Shares Float 24 (M)
% Held by Insiders 0.2 (%)
% Held by Institutions 107 (%)
Shares Short 2,020 (K)
Shares Short P.Month 2,700 (K)

Stock Financials

EPS 7.13
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 17.82
Profit Margin (%) 57.4
Operating Margin (%) 71.1
Return on Assets (ttm) 23.7
Return on Equity (ttm) 51.8
Qtrly Rev. Growth -81.4
Gross Profit (p.s.) 9.68
Sales Per Share 12.76
EBITDA (p.s.) 9.09
Qtrly Earnings Growth -98.5
Operating Cash Flow -143 (M)
Levered Free Cash Flow -229 (M)

Stock Valuations

PE Ratio 2.79
PEG Ratio 0
Price to Book value 1.11
Price to Sales 1.56
Price to Cash Flow -4.97

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.